Targeting sphingosine kinase-1 to inhibit melanoma
Article first published online: 22 FEB 2012
© 2012 John Wiley & Sons A/S
Pigment Cell & Melanoma Research
Volume 25, Issue 2, pages 259–274, March 2012
How to Cite
Madhunapantula, S. V., Hengst, J., Gowda, R., Fox, T. E., Yun, J. K. and Robertson, G. P. (2012), Targeting sphingosine kinase-1 to inhibit melanoma. Pigment Cell & Melanoma Research, 25: 259–274. doi: 10.1111/j.1755-148X.2012.00970.x
- Issue published online: 22 FEB 2012
- Article first published online: 22 FEB 2012
- Accepted manuscript online: 11 JAN 2012 10:53AM EST
- PUBLICATION DATA Received 7 April 2011, revised and accepted for publication 6 January 2012, published online 11 January 2012
Figure S1. SKI-I inhibits vertical growth phase melanoma cells viability. 5 × 103 WM278.1 cells containing high SPHK1 activity were exposed to increasing concentrations of SKI-I for 24, 48, and 72 h and cell viability measured using MTS.
Figure S2. SKI-I but not SKI-II reduces cellular S-1-P and induced pro-apoptotic ceramide content in 1205 Lu melanoma cells.
Figure S3. Intraperitoneal administration of SKI-I but not SKI-II retarded melanoma tumor growth.
Figure S4. SKI-I elevates caspase-3/7 activity in melanoma cells. A375M, UACC 903, and 1205 Lu cells were treated with 1, 2.5, and 5.0 μM SKI-I for 72 h and cell lysates analyzed for caspase-3/7 activity using Apo-ONE homogenous caspase-3/7 activity assay kit.
|PCMR_970_sm_fs1.jpg||97K||Supporting info item|
|PCMR_970_sm_fs2.jpg||115K||Supporting info item|
|PCMR_970_sm_fs3.jpg||143K||Supporting info item|
|PCMR_970_sm_fs4.jpg||108K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.